Previous Close | 5.0900 |
Open | 5.0300 |
Bid | 4.7700 x 400 |
Ask | 4.8300 x 400 |
Day's Range | 4.7600 - 5.0500 |
52 Week Range | 2.2500 - 7.9900 |
Volume | |
Avg. Volume | 221,316 |
Market Cap | 109.341M |
Beta (5Y Monthly) | 0.51 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.9400 |
Earnings Date | May 10, 2024 - May 14, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 18.40 |
Revenue Falls Short While R&D Expenses Decrease Compared to Analyst Estimates
Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported recent business highlights and financial results for the fourth quarter and full year ended December 31, 2023.
Delcath Systems, Inc. ( NASDAQ:DCTH ) insiders who bought shares over the past year were rewarded handsomely last week...